Article
Medicine, General & Internal
Federica Filippini, Mauro Giacomelli, Chiara Bazzani, Micaela Fredi, Paolo Semeraro, Cesare Tomasi, Franco Franceschini, Arnaldo Caruso, Ilaria Cavazzana, Cinzia Giagulli
Summary: This study analyzed the impact of immunosuppressive therapies on the efficacy of COVID-19 vaccines. The results showed that patients treated with abatacept had a weaker humoral and T cell response after two doses of the vaccine. However, the third vaccine dose was able to enhance the antibody response to balance the impaired T cell-mediated response. All patients treated with immunosuppressive drugs were able to generate specific CD4-activated T cells after spike protein stimulation.
Article
Immunology
Martina Fabris, Ginevra De Marchi, Rossana Domenis, Federica Caponnetto, Silvia Guella, Chiara Dal Secco, Nicola Cabas, Salvatore De Vita, Antonio Paolo Beltrami, Francesco Curcio, Luca Quartuccio
Summary: This study evaluated the immune response to SARS-CoV-2 mRNA vaccination in patients with complex or rare systemic autoimmune diseases who were previously treated with or under continuous treatment with B-cell-targeted therapies. The results showed that even in the absence of circulating B cells, virus-specific cellular immunity can be induced, indicating that B-cell-targeted therapies do not preclude SARS-CoV-2 vaccination.
JOURNAL OF AUTOIMMUNITY
(2022)
Article
Rheumatology
Leonie Maria Frommert, Amanthi Nadira Arumahandi de Silva, Jan Zernicke, Veronika Scholz, Tanja Braun, Lara Maria Jeworowski, Tatjana Schwarz, Pinkus Tober-Lau, Alexander ten Hagen, Elisa Habermann, Florian Kurth, Leif Erik Sander, Victor Max Corman, Gerd-Ruediger Burmester, Robert Biesen, Fredrik N. Albach, Jens Klotsche
Summary: This study aimed to identify factors leading to a diminished humoral vaccination response in patients with autoimmune rheumatic diseases (AIRD) after COVID-19 vaccination. The study found that certain immunosuppressive therapies, vaccine type, age, and vaccination interval can affect the antibody response in these patients.
Article
Rheumatology
Michaela Koehm, Maximilian Klippstein, Stephanie Dauth, Konstantin Hallmann, Niko Kohmer, Harald Burkhardt, Sandra Ciesek, Gerd Geisslinger, Holger F. Rabenau, Frank Behrens
Summary: This study evaluated the potential of immunosuppressed patients to mount B-cell and T-cell responses to COVID-19 booster vaccination. The results showed that patients with therapeutic B-cell depletion had low antibody levels before and after vaccination, but showed significantly higher T-cell responses. Primary immunodeficiency had a stronger impact on antiviral immune response compared to other immunosuppressed conditions.
Article
Rheumatology
Christian Ammitzboll, Marianne Kragh Thomsen, Jakob Bogh Andersen, Jens Magnus Berth Jensen, Marie-Louise From Hermansen, Anders Dahl Johannsen, Mads Lamm Larsen, Clara Elbaek Mistegaard, Susan Mikkelsen, Fruzsina Szabados, Signe Risbol Vils, Christian Erikstrup, Ellen-Margrethe Hauge, Anne Troldborg
Summary: This study aimed to investigate the effect of either a booster vaccine or revaccination on the antibody response to COVID-19 mRNA vaccines in rheumatic disease patients treated with rituximab. The study found that most patients had impaired humoral response after the booster dose or revaccination, and approximately one-third of the patients showed seroconversion. Measurable B cells before boosting or revaccination were the strongest predictor of antibody response.
Article
Medicine, General & Internal
Denise Miyamoto, Claudia Giuli Santi, Celina Wakisaka Maruta, Valeria Aoki
Summary: Autoimmune blistering diseases are rare and potentially life-threatening dermatoses. Treating these diseases during the COVID-19 pandemic is challenging and requires considering individual factors and infectious risks.
FRONTIERS IN MEDICINE
(2022)
Review
Medicine, General & Internal
Anna Pira, Jo Linda Maria Sinagra, Francesco Moro, Feliciana Mariotti, Giovanni Di Zenzo
Summary: Autoimmune bullous diseases (AIBDs) are life-threatening disorders associated with blistering. The COVID-19 pandemic has had a heavy impact on AIBD patients, who are considered fragile due to their increased risk of infections.
FRONTIERS IN MEDICINE
(2023)
Review
Rheumatology
Mehmet Soy, Gokhan Keser, Pamir Atagunduz, Melek Yalcin Mutlu, Alper Gunduz, Gizem Koybasi, Cemal Bes
Summary: The article discusses the importance of COVID-19 vaccination in AIIRD patients and provides precautions to be taken before vaccination, including vaccination when disease activity is under control and before the use of biological DMARDs.
CLINICAL RHEUMATOLOGY
(2021)
Article
Immunology
Azam Safary, Kamal Esalatmanesh, Amir Taher Eftekharsadat, Mohammad -Reza Jafari Nakjavani, Alireza Khabbazi
Summary: Vaccination against COVID-19 is important for achieving herd immunity and controlling the pandemic. However, a small number of people may develop autoimmune rheumatic diseases (ARDs) as a rare adverse reaction to the vaccines. This study identifies individuals who developed de-novo ARDs after COVID-19 vaccination, with a higher prevalence among those who received the AstraZeneca vaccine. Prompt diagnosis and treatment can prevent irreversible organ damage.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Immunology
Anna Vanni, Lorenzo Salvati, Alessio Mazzoni, Giulia Lamacchia, Manuela Capone, Stefania Francalanci, Seble Tekle Kiros, Lorenzo Cosmi, Benedetta Puccini, Manuel Ciceri, Benedetta Sordi, Gian Maria Rossolini, Francesco Annunziato, Laura Maggi, Francesco Liotta
Summary: Patients with B-cell lymphoma have impaired vaccination response, especially after chemotherapy. Understanding the immune response status is crucial for personalized immunization strategies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, Research & Experimental
Yuxue Nie, Jingna Li, Di Wu, Yunjiao Yang, Li Zhang, Wei Bai, Nan Jiang, Lin Qiao, Can Huang, Shuang Zhou, Xinping Tian, Mengtao Li, Xiaofeng Zeng, Linyi Peng, Wen Zhang
Summary: This retrospective study investigated the trajectory of B-cell repopulation and associated factors in patients with autoimmune diseases who underwent rituximab treatment. The results showed significant differences in B-cell repopulation time among patients with different autoimmune diseases. Higher levels of IgA and concurrent glucocorticoid use were found to be associated with B-cell repopulation. Latent class trajectory modeling identified a specific cluster of patients who demonstrated prolonged B-cell depletion after rituximab treatment.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Review
Immunology
Laura Macca, Lucia Peterle, Manuela Ceccarelli, Ylenia Ingrasciotta, Giuseppe Nunnari, Claudio Guarneri
Summary: An increasing number of cases of new-onset or worsening vitiligo have been reported following COVID-19 vaccination, suggesting a potential autoimmune trigger.
Article
Rheumatology
Ioana Andreica, Arturo Blazquez-Navarro, Jan Sokolar, Moritz Anft, Uta Kiltz, Stephanie Pfaender, Elena Vidal Blanco, Timm Westhoff, Nina Babel, Ulrik Stervbo, Xenofon Baraliakos
Summary: This study investigated the impact of different immunosuppressive therapies on humoral and cellular responses after vaccination in patients with autoimmune inflammatory rheumatic diseases (AIRDs). The results showed that the majority of patients developed neutralizing antibodies after the second vaccination, with the highest titers seen in patients on IL-17i. There was no difference in cellular immune response among different therapies.
Article
Medicine, General & Internal
Chutima Seree-aphinan, Kumutnart Chanprapaph, Ploysyne Rattanakaemakorn, Chavachol Setthaudom, Thanitta Suangtamai, Cherrin Pomsoong, Yanisa Ratanapokasatit, Poonkiat Suchonwanit
Summary: The study found that dermatological patients on certain immunosuppressive drugs had lower levels of immune response to the Sinovac-CoronaVac vaccine, while those on other medications or biologics had similar immunogenic profiles to those not receiving immunosuppressive therapy. Although not statistically significant, a reduction in humoral immune response was observed in patients using two or more immunosuppressants or those with pemphigus. These findings suggest that some patients with immune-mediated skin conditions may benefit from vaccines that elicit a higher level of immunogenicity or booster doses.
FRONTIERS IN MEDICINE
(2021)
Article
Dermatology
Hui Fang, Ke Xue, Tianyu Cao, Qingyang Li, Erle Dang, Yanghe Liu, Jieyu Zhang, Pei Qiao, Jiaoling Chen, Jingyi Ma, Shengxian Shen, Bingyu Pang, Yaxing Bai, Hongjiang Qiao, Shuai Shao, Gang Wang
Summary: Bullous pemphigoid (BP) is an autoimmune bullous skin disease characterized by autoantibodies against skin proteins. B-cell-targeting biologics have shown effectiveness in BP, indicating the role of B cells in its pathogenesis. In this study, researchers found that the CXCL12/CXCR4 axis plays a pathogenic role in modulating B-cell trafficking and differentiation in BP, and targeting CXCR4 could be a potential strategy for BP treatment.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)